Short-term efficacy and safety of sitagliptin treatment in long-term stable renal recipients with new-onset diabetes after transplantation
The DOI matches its Crossref record; 55 of the 55 references it cites were found in a registry or an index.
Abstract
BACKGROUND: New-onset diabetes after transplantation (NODAT) is a common complication after renal transplantation. There are limited available oral drugs to treat hyperglycaemia in this population owing to reduced renal function, potential interactions with immunosuppressive drugs and adverse effects such as hypoglycaemic events that may increase the cardiovascular risk. This study was initiated to investigate efficacy and safety of sitagliptin treatment that may represent a novel alternative in renal transplant recipients. METHODS: Nineteen long-term stable renal transplant recipients with NODAT were included in a controlled, cross-over study and randomized to first receive either sitagliptin 50-100 mg/day or a sitagliptin-free period of 4 weeks. Median age (interquartile range, IQR) was 67 (62-72) years (12 males/7 females), all studied 1 (1-3) year after transplantation. The immunosuppressive regimen was a triple calcineurin inhibitor-based therapy. Oral glucose tolerance test (OGTT) with insulin and C-peptide responses and laser Doppler (LD) flowmetry assessment of endothelial function were performed at baseline and after each treatment period. Home measurements of plasma glucose were performed daily during the study. RESULTS: The median (IQR) first- and second-phase insulin secretion responses increased significantly by 56.3% (45.2-112.6%, P = 0.005) and 39.3% (26.5-81.0%, P = 0.006), respectively, following sitagliptin treatment as compared with no sitagliptin treatment. Fasting and 2-h plasma glucose concentrations fell significantly {0.9 mmol/L [0.5-1.7 mmol/L (16.2 mg/dL), P = 0.003] and 2.9 mmol/L [0.5-6.4 mmol/L (52.3 mg/dL), P = 0.004], respectively}, as did also home measurements of plasma glucose. Endothelial function and plasma markers of cardiovascular risk were unaffected. No serious adverse events were observed. Two mild and asymptomatic hypoglycaemic episodes were observed in combination with glipizide. CONCLUSIONS: Sitagliptin increases insulin secretion and reduces fasting and postprandial plasma glucose in renal transplant recipients with NODAT. The short-term treatment was well tolerated, and sitagliptin seems safe in this population.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“At this time, most of the literature is in the form of case reports demonstrating hyperglycemia, new-onset diabetes, and DKA, either with or without autoimmune markers of T1D.1579,1600–1605”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [1600]
In the citing paper
“An increasing body of new literature points to the association of immune checkpoint inhibitors with new-onset hyperglycemia and DM.”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [1600]
Citations
Cites
Matthews, D. R., Hosker, J. P., Rudenski, A. S., Naylor, B. A., Treacher, D. F., & Turner, R. C. (1985) · Diabetologia · doi:10.1007/bf00280883 · Cited by 31,502
Standards of medical care in diabetes—2013
American Diabetes Association (2013) · Diabetes Care · doi:10.2337/dc13-s011 · Cited by 4,369
Levey, A. S., Coresh, J., Greene, T., Marsh, J., Stevens, L. A., Kusek, J. W., Van Lente, F., & for Chronic Kidney Disease Epidemiology Collaboration (2007) · Clinical Chemistry · doi:10.1373/clinchem.2006.077180 · Cited by 1,855
Diabetes Mellitus after Kidney Transplantation in the United States
Kasiske, B. L., Snyder, J. J., Gilbertson, D., & Matas, A. J. (2003) · American Journal of Transplantation · doi:10.1034/j.1600-6143.2003.00010.x · Cited by 1,285
Use of the oral glucose tolerance test to assess insulin release and insulin sensitivity.
Stumvoll, M., Mitrakou, A., Pimenta, W., Jenssen, T., Yki-Järvinen, H., Van Haeften, T., Renn, W., & Gerich, J. (2000) · Diabetes Care · doi:10.2337/diacare.23.3.295 · Cited by 1,042
Self-citationHoldaas, H., Fellström, B., Jardine, A. G., Holme, I., Nyberg, G., Fauchald, P., Grönhagen-Riska, C., Madsen, S., Neumayer, H.-H., Cole, E., et al. (2003) · The Lancet · doi:10.1016/s0140-6736(03)13638-0 · Cited by 919
Self-citationGlucose Toxicity in β-Cells: Type 2 Diabetes, Good Radicals Gone Bad, and the Glutathione Connection
Robertson, R. P., Harmon, J., Tran, P. O., Tanaka, Y., & Takahashi, H. (2003) · Diabetes · doi:10.2337/diabetes.52.3.581 · Cited by 897
(1973) · New England Journal of Medicine · doi:10.1056/nejm197307122890231 · Cited by 895
Charbonnel, B., Karasik, A., Liu, J., Wu, M., Meininger, G., & for the Sitagliptin Study 020 Group (2006) · Diabetes Care · doi:10.2337/dc06-0706 · Cited by 790
Nathan, D. M., Buse, J. B., Davidson, M. B., Ferrannini, E., Holman, R. R., Sherwin, R., & Zinman, B. (2009) · Diabetologia · doi:10.1007/s00125-008-1157-y · Cited by 712 · cited 1×
“Current guidelines for treating type 2 diabetes mellitus (T2DM) primarily recommend life style interventions and, if needed, additional treatment with oral glucose-lowering agents or insulin [7].”
Background
Research works printed but not linked: 3
- 2012, 2012, 569
- Li, 2011, Chinese medical journal, 124, 3607
- Kubota, 2012, 4, 309
Cited by
2. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes—2022
American Diabetes Association Professional Practice Committee (2022) · Diabetes Care · doi:10.2337/dc22-s002 · Cited by 4,792
2. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes—2020
American Diabetes Association (2020) · Diabetes Care · doi:10.2337/dc20-s002 · Cited by 3,187
“Dipeptidyl peptidase 4 inhibitors do not interact with immunosuppressant drugs and have demonstrated safety in small clinical trials (100,101).”
Background2. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes—2018
American Diabetes Association (2018) · Diabetes Care · doi:10.2337/dc18-s002 · Cited by 3,159
2. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes—2021
American Diabetes Association (2021) · Diabetes Care · doi:10.2337/dc21-s002 · Cited by 3,116
2. Classification and Diagnosis of Diabetes:Standards of Medical Care in Diabetes—2019
American Diabetes Association (2019) · Diabetes Care · doi:10.2337/dc19-s002 · Cited by 2,697
2. Classification and Diagnosis of Diabetes:Standards of Care in Diabetes—2023
ElSayed, N. A., Aleppo, G., Aroda, V. R., Bannuru, R. R., Brown, F. M., Bruemmer, D., Collins, B. S., Gaglia, J. L., Hilliard, M. E., Isaacs, D., et al. (2023) · Diabetes Care · doi:10.2337/dc23-s002 · Cited by 2,433
Sharif, A., Hecking, M., de Vries, A. P. J., Porrini, E., Hornum, M., Rasoul-Rockenschaub, S., Berlakovich, G., Krebs, M., Kautzky-Willer, A., Schernthaner, G., et al. (2014) · American Journal of Transplantation · doi:10.1111/ajt.12850 · Cited by 532
“Halden et al (52) have also reported the short-term efficacy and safety of a different dipeptidylpeptidase-4 inhibitor (sitagliptin) in their randomized crossover study of 19 kidney allograft recipients with PTDM.”
BackgroundSelf-citationBlonde, L., Umpierrez, G. E., Reddy, S. S., McGill, J. B., Berga, S. L., Bush, M., Chandrasekaran, S., DeFronzo, R. A., Einhorn, D., Galindo, R. J., et al. (2022) · Endocrine Practice · doi:10.1016/j.eprac.2022.08.002 · Cited by 507
Post-transplant diabetes mellitus in patients with solid organ transplants
Jenssen, T., & Hartmann, A. (2019) · Nature Reviews Endocrinology · doi:10.1038/s41574-018-0137-7 · Cited by 278
Self-citationInternational consensus on post-transplantation diabetes mellitus
Sharif, A., Chakkera, H. A., de Vries, A. P. J., Eller, K., Guthoff, M., Haller, M. C., Hornum, M., Nordheim, E., Kautzky‐Willer, A., Krebs, M., et al. (2023) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfad258 · Cited by 145
Self-citationNew-onset diabetes mellitus after kidney transplantation: Current status and future directions
Palepu, S. (2015) · World Journal of Diabetes · doi:10.4239/wjd.v6.i3.445 · Cited by 119
Scheen, A. J. (2015) · Clinical Pharmacokinetics · doi:10.1007/s40262-014-0198-2 · Cited by 102
“The treatment was well tolerated, and sitagliptin seems safe in this population [49, 50].”
BackgroundPost-transplantation diabetes—state of the art
Sharif, A., & Cohney, S. J. (2015) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(15)00387-3 · Cited by 99
Emerging treatments for post-transplantation diabetes mellitus
Jenssen, T., & Hartmann, A. (2015) · Nature Reviews Nephrology · doi:10.1038/nrneph.2015.59 · Cited by 90
Self-citationConte, C., & Secchi, A. (2018) · Acta Diabetologica · doi:10.1007/s00592-018-1137-8 · Cited by 81
Post-Transplantation Diabetes Mellitus
Ahmed, S. H., Biddle, K., Augustine, T., & Azmi, S. (2020) · Diabetes Therapy · doi:10.1007/s13300-020-00790-5 · Cited by 77
GLP-1 Restores Altered Insulin and Glucagon Secretion in Posttransplantation Diabetes
Halden, T. A. S., Egeland, E. J., Åsberg, A., Hartmann, A., Midtvedt, K., Khiabani, H. Z., Holst, J. J., Knop, F. K., Hornum, M., Feldt-Rasmussen, B., et al. (2016) · Diabetes Care · doi:10.2337/dc15-2383 · Cited by 67
Self-citationMetabolic Disorders with Kidney Transplant
Cohen, E., Korah, M. M., Callender, G. G., Aguiar, R. B. D., & Haakinson, D. J. (2020) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.09310819 · Cited by 65
Use of Empagliflozin in Recipients of Kidney Transplant: A Report of 8 Cases
Attallah, N., & Yassine, L. (2019) · Transplantation Proceedings · doi:10.1016/j.transproceed.2019.05.023 · Cited by 62
Management of metabolic syndrome and cardiovascular risk after liver transplantation
Fatourou, E. M., & Tsochatzis, E. A. (2019) · The Lancet Gastroenterology & Hepatology · doi:10.1016/s2468-1253(19)30181-5 · Cited by 59
Vanhove, T., Remijsen, Q., Kuypers, D. R. J., & Gillard, P. (2016) · Transplantation Reviews · doi:10.1016/j.trre.2016.09.001 · Cited by 56
Diabetes Care After Transplant
Wallia, A., Illuri, V., & Molitch, M. E. (2016) · Medical Clinics of North America · doi:10.1016/j.mcna.2016.01.005 · Cited by 50
Post-Transplant Diabetes Mellitus and Prediabetes in Renal Transplant Recipients: An Update
Rodríguez‐Rodríguez, A. E., Porrini, E., Hornum, M., Donate‐Correa, J., Febles, R. M., Ramchand, S. K., Lima, M. X. M., & Torres, A. (2021) · The Nephron journals/Nephron journals · doi:10.1159/000514288 · Cited by 50
Non-immunological complications following kidney transplantation
Cohen‐Bucay, A., Gordon, C. E., & Francis, J. M. (2019) · F1000Research · doi:10.12688/f1000research.16627.1 · Cited by 49
Lo, C., Jun, M., Badve, S. V., Pilmore, H., White, S. L., Hawley, C., Cass, A., Perkovic, V., & Zoungas, S. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd009966.pub2 · Cited by 41
Langsford, D., & Dwyer, K. (2015) · World Journal of Diabetes · doi:10.4239/wjd.v6.i10.1132 · Cited by 44
Lee, S. A., Verhoeff, R., Hullekes, F. E., Hansrivijit, P., de Bruin, R. W. F., Porte, R. J., & Riella, L. V. (2025) · Transplantation · doi:10.1097/tp.0000000000005496 · Cited by 43
Vest, L. S., Koraishy, F. M., Zhang, Z., Lam, N. N., Schnitzler, M. A., Dharnidharka, V. R., Axelrod, D., Naik, A. S., Alhamad, T. A., Kasiske, B. L., et al. (2018) · Clinical Transplantation · doi:10.1111/ctr.13302 · Cited by 41
Prabhahar, A., Batta, A., Hatwal, J., Kumar, V., Ramachandran, R., & Batta, A. (2024) · World Journal of Transplantation · doi:10.5500/wjt.v15.i1.97458 · Cited by 37
Management of diabetes mellitus in patients undergoing liver transplantation
Grancini, V., Resi, V., Palmieri, E., Pugliese, G., & Orsi, E. (2019) · Pharmacological Research · doi:10.1016/j.phrs.2019.01.042 · Cited by 36
Impact of dipeptidyl-peptidase 4 inhibitors on cardiovascular diseases
Xie, W., Song, X., & Liu, Z. (2018) · Vascular Pharmacology · doi:10.1016/j.vph.2018.05.010 · Cited by 33
Pisano, G., Fracanzani, A. L., Caccamo, L., Donato, M. F., & Fargion, S. R. (2016) · World Journal of Gastroenterology · doi:10.3748/wjg.v22.i40.8869 · Cited by 31
Lo, C., Toyama, T., Oshima, M., Jun, M., Chin, K. L., Hawley, C. M., & Zoungas, S. (2020) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd009966.pub3 · Cited by 30
Risk assessment and management of post-transplant diabetes mellitus
Han, E., Kim, M. S., Kim, Y. S., & Kang, E. S. (2016) · Metabolism · doi:10.1016/j.metabol.2016.07.011 · Cited by 30
Role of dipeptidyl peptidase-4 inhibitors in new-onset diabetes after transplantation
Lim, S. W., Jin, J. Z., Jin, L. G., Jin, J., & Li, C. (2015) · The Korean Journal of Internal Medicine · doi:10.3904/kjim.2015.30.6.759 · Cited by 28
Review of Newer Antidiabetic Agents for Diabetes Management in Kidney Transplant Recipients
Anderson, S., Cotiguala, L., Tischer, S. M., Park, J. M., & McMurry, K. A. (2020) · Annals of Pharmacotherapy · doi:10.1177/1060028020951955 · Cited by 28
Oikonomaki, D., Dounousi, E. C., Duni, Α., Roumeliotis, S. K., & Liakopoulos, V. (2020) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2020.108604 · Cited by 26
Jin, L. G., Lim, S. W., Doh, K. C., Piao, S. G., Jin, J., Heo, S. B., Chung, B. H., & Yang, C. W. (2014) · PLoS ONE · doi:10.1371/journal.pone.0100798 · Cited by 26
Hyperglycemia management in patients with posttransplantation diabetes
Galindo, R. J., Fried, M., Breen, T., & Tamler, R. (2016) · Endocrine Practice · doi:10.4158/ep151039.ra · Cited by 25
Management of post-transplant diabetes mellitus: an opportunity for novel therapeutics
Montero, N., Oliveras, L., Soler, M. J., & Cruzado, J. M. (2021) · Clinical Kidney Journal · doi:10.1093/ckj/sfab131 · Cited by 25
Abdelaziz, T. S., Ali, A. Y., & Fatthy, M. (2019) · Current Diabetes Reviews · doi:10.2174/1573399815666190321144310 · Cited by 25
Lawrence, S. E., Chandran, M. M., Park, J. M., Sweiss, H., Jensen, T. B., Choksi, P. U., & Crowther, B. R. (2023) · Clinical Transplantation · doi:10.1111/ctr.14922 · Cited by 23
Hepatitis C virus infection and diabetes
Das, G. C., & Bolusani, H. (2016) · Practical Diabetes · doi:10.1002/pdi.2017 · Cited by 22
Diabetes in Kidney Transplantation
Cantarin, M. P. M. (2021) · Advances in Chronic Kidney Disease · doi:10.1053/j.ackd.2021.10.004 · Cited by 18
Post‐transplantation diabetes mellitus: evaluation of treatment strategies
Haidinger, M., Antlanger, M., Kopecky, C., Kovarik, J. J., Säemann, M. D., & Werzowa, J. M. (2015) · Clinical Transplantation · doi:10.1111/ctr.12541 · Cited by 17
New-onset diabetes mellitus after renal transplantation
Goldmannová, D., Karásek, D., Krystyník, O., & Zadražil, J. (2016) · Biomedical Papers · doi:10.5507/bp.2016.005 · Cited by 16
Incretin-based therapy: renal effects
Korbut, A. I., & Klimontov, V. V. (2016) · Diabetes Mellitus · doi:10.14341/dm7727 · Cited by 16
Sridhar, V. S., Ambinathan, J. P. N., Gillard, P., Mathieu, C., Cherney, D. Z. I., Lytvyn, Y., & Singh, S. K. (2021) · Transplantation · doi:10.1097/tp.0000000000003919 · Cited by 15
Antidiabetic therapy in post kidney transplantation diabetes mellitus
Werzowa, J. M., Säemann, M. D., Haidinger, M., Krebs, M., & Hecking, M. (2015) · Transplantation Reviews · doi:10.1016/j.trre.2015.01.001 · Cited by 14
Renal posttransplantation diabetes mellitus: An overview
Pimentel, A. L., Bauer, A. C., & Camargo, J. L. (2015) · Clinica Chimica Acta · doi:10.1016/j.cca.2015.09.010 · Cited by 13
Senior, P. A., Almehthel, M. S., Miller, A., & Paty, B. W. (2018) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2017.10.017 · Cited by 13
Diabetic Kidney Disease in Post-Transplant Diabetes Mellitus: Causes, Treatment and Outcomes
Lim, L., Chang, J., & Kuo, H. (2023) · Biomedicines · doi:10.3390/biomedicines11020470 · Cited by 12
Klangjareonchai, T., Eguchi, N., Tantisattamo, E., Ferrey, A., Reddy, U. G., Dafoe, D. C., & Ichii, H. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13030413 · Cited by 12
Thiruvengadam, S., Hutchison, B., Lim, W., Bennett, K., Daniels, G., Cusack, N., Jacques, A., Cawley, B., Thiruvengadam, S., & Chakera, A. (2019) · Diabetes & Metabolic Syndrome: Clinical Research & Reviews · doi:10.1016/j.dsx.2019.04.020 · Cited by 11
Phillips, J., Chen, J. H. C., Ooi, E. M. M., Prunster, J., & Lim, W. H. (2021) · Frontiers in Clinical Diabetes and Healthcare · doi:10.3389/fcdhc.2021.731574 · Cited by 11
Kanbay, M., Çöpür, S., Uçku, D., & Zoccali, C. (2022) · Clinical Kidney Journal · doi:10.1093/ckj/sfac216 · Cited by 10
Diabetic Kidney Disease in Post-Kidney Transplant Patients
Pham, N.-Y. T., Cruz, D., Marin, L. M., Ravender, R., & García, P. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13030793 · Cited by 9
New onset of diabetes after transplant
Egan, L., & Sheejo, S. (2019) · Journal of Kidney Care · doi:10.12968/jokc.2019.4.4.180 · Cited by 7
Nonallograft Complications of Lung Transplantation
Thaniyavarn, T., Grewal, H. S., Goldberg, H. J., & Arcasoy, S. M. (2022) · Thoracic surgery clinics/Thorac. surg. clin. · doi:10.1016/j.thorsurg.2022.01.004 · Cited by 6
Posttransplantationsdiabetes mellitus: Eine Herausforderung für die Nachsorge
Albersmeyer, M., Gehr, B., Liebl, A., & Gerbig, D. (2020) · Der Nephrologe · doi:10.1007/s11560-020-00436-4 · Cited by 6
Khan, A. A., Ali, M. M., & Hamer, R. (2025) · Cureus · doi:10.7759/cureus.97193 · Cited by 5
Kanbay, M., Abdel‐Rahman, S. M., Güldan, M., Özbek, L., Genc, N. I., Ak, A. B., Covic, A. C., & Goren, H. K. (2026) · Clinical Kidney Journal · doi:10.1093/ckj/sfag105 · Cited by 5
Efficacy and safety of Sodium-Glucose-Transporter-2 inhibitors in kidney transplant patients
Jenssen, T. G. (2021) · Current Opinion in Nephrology & Hypertension · doi:10.1097/mnh.0000000000000749 · Cited by 5
Self-citationBratsiakou, A., Papasotiriou, M., Ntrinias, T., Tsiotsios, K., Papachristou, E. C., & Goumenos, D. S. (2021) · Experimental and Clinical Transplantation · doi:10.6002/ect.2020.0519 · Cited by 5
Interdisciplinary problem of post-transplant diabetes mellitus: literature review
Владимировна, Б. А., Mustafina, V. R., & Glinkina, I. V. (2021) · Sechenov Medical Journal · doi:10.47093/2218-7332.2021.12.1.60-73 · Cited by 4
Sanyal, D., Biswas, M., & Chaudhari, N. (2020) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2020.11.019 · Cited by 4
Schmid, F., Mayer, C., Büttner-Herold, M. J., von Hörsten, S., Amann, K., & Daniel, C. (2021) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2021.108691 · Cited by 4
Linagliptin in the Management of Type 2 Diabetes Mellitus After Kidney Transplant
Attallah, N. M., & Yassine, L. (2021) · Transplantation Proceedings · doi:10.1016/j.transproceed.2021.07.035 · Cited by 4
Hu, S., & Lan, G. (2025) · Frontiers in Medicine · doi:10.3389/fmed.2025.1653147 · Cited by 3
New-Onset Diabetes after Kidney Transplantation: Diagnosis, Risk Factors, and Management
Bulum, T., Prkačin, I., & Duvnjak, L. S. (2020) · Acta Clinica Croatica · doi:10.20471/acc.2021.60.s1.13 · Cited by 3
Treating posttransplantation diabetes mellitus
Pérez‐Sáez, M. J., Marín-Casino, M., & Pascual, J. (2015) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2015.1039983 · Cited by 3
Novel Glucose-Lowering Therapies in the Setting of Solid Organ Transplantation
Nissaisorakarn, P., Pavlakis, M., & Aala, A. (2021) · Advances in Chronic Kidney Disease · doi:10.1053/j.ackd.2021.03.001 · Cited by 3
Sitagliptin—balancing cardiovascular risk, hyperglycaemia and safety
Razzak, M. (2014) · Nature Reviews Nephrology · doi:10.1038/nrneph.2014.18 · Cited by 2
Shukla, S., Kumar, A., Kumar, A., & Mishra, R. (2025) · Asian Journal of Chemistry · doi:10.14233/ajchem.2025.33803 · Cited by 2
Newer Drugs for Type 2 Diabetes: An Emerging Adjunctive Therapy to Insulin for Type 1 Diabetes?
Aeng, E. S. Y., Boucher, M., & Severn, M. (2016) · Cited by 2
Management of Diabetes in Organ Transplant Patients
Yun, Y., & Kang, E. S. (2014) · Journal of Korean Diabetes · doi:10.4093/jkd.2014.15.3.134 · Cited by 1
The causes of development and methods of correction of post-transplant diabetes mellitus
Lasareva, K. E., Николаевна, Р. О., & Zagorodnikova, N. V. (2017) · Transplantologiya The Russian Journal of Transplantation · doi:10.23873/2074-0506-2017-9-4-335-349 · Cited by 1
Diabetes in Kidney Transplant Recipients
Dhital, S. M. (2018) · Springer eBooks · doi:10.1007/978-3-030-00132-2_10 · Cited by 1
Munuaispotilaiden diabeteksen glukoositasapainon hoito
Paajanen, H., & Tuomilehto, J. (2019) · Helda - University of Helsinki Institutional Repository · Cited by 1
Shamshad, F., Tungsanga, S., Senior, P. A., Shojai, S., Ghimire, A., Ye, F., Kung, J. Y. C., Hariramani, V. K., Abdulrahman, A., Penney, M., et al. (2024) · BMJ Open · doi:10.1136/bmjopen-2023-078393 · Cited by 1
Post-liver transplantation diabetes mellitus — a clinical challenge for diabetologists?
Bhadada, S. K., & Pal, R. (2021) · International Journal of Diabetes in Developing Countries · doi:10.1007/s13410-021-00955-3 · Cited by 1
Post-transplantasjons-diabetes mellitus i nyretransplanterte pasienter: En bihormonell sykdom
Egeland, E. J. (2015) · NORA - Norwegian Open Research Archives
Терапия, основанная на инкретинах: почечные эффекты
Korbut, A. I., & Klimontov, V. V. (2016) · Diabetes Mellitus
Improving Drug Use and Dosing in Chronic Kidney Disease
Peter, W. L. S., Wazny, L. D., & Hudson, J. Q. (2018) · Elsevier eBooks · doi:10.1016/b978-0-323-52978-5.00017-3
La terapia del diabete nel paziente nefropatico
Mannucci, E., & Dicembrini, I. (2015) · Giornale di Clinica Nefrologica e Dialisi · doi:10.33393/gcnd.2015.801
La terapia del diabete nel paziente nefropatico
Mannucci, E., & Dicembrini, I. (2015) · Giornale di Techniche Nefrologiche e Dialitiche · doi:10.5301/gtnd.2015.14823
Yang, X., Li, Z., Cai, Q., Cui, Y., Deng, H., Xu, W., Peng, W., Wang, R., Huang, H., Chen, J., et al. (2022) · Research Square · doi:10.21203/rs.3.rs-1894397/v1
Treatment strategy in post-transplant diabetes
Elazizi, L., Melki, F. Z., Aynaou, H., Salhi, H., & Ouahabi, H. E. (2022) · Cahiers Santé Médecine thérapeutique · doi:10.1684/sanmt.2023.163
Post-Transplantations-Diabetes mellitus: Häufige Komplikation nach Transplantation
Ott, U. (2023) · Nephrologie aktuell · doi:10.1055/a-2055-3728
Post Transplantation Diabetes Mellitus
Lamacchia, O. (2023) · The Journal of AMD · doi:10.36171/jamd23.26.2.6
Management of new onset dysglycemia in transplant recipients
Sharif, A. (2024) · Elsevier eBooks · doi:10.1016/b978-0-323-85732-1.00045-1
Lee, K. Y., Song, G. Y., Seo, M. J., Kim, S. H., Kang, D. R., Park, K., Kim, J. T., Park, S. W., & Lee, J. Y. (2025) · Transplantation Proceedings · doi:10.1016/j.transproceed.2024.12.014
Ali, S. (2020) · American Diabetes Association eBooks · doi:10.2337/9781580406314.ch01
Metadata
- Authors
- Strom Halden, T. A., Asberg, A., Vik, K., Hartmann, A., & Jenssen, T.
- Affiliations
- Oslo University Hospital (NO)
- ORCID
- Jenssen, T.
- Venue
- Nephrology Dialysis Transplantation
- Publisher
- Oxford University Press (OUP)
- Published
- 2014-01-22
- Volume
- 29
- Issue
- 4
- Pages
- 926-933
- ISSN
- 0931-0509 (ISSN-L)
- 1460-2385
- OpenAlex
- W2171947907
- Cited by
- 89
- References
- 55
- Citations by year
- 2026: 1 · 2025: 5 · 2024: 4 · 2023: 5 · 2022: 5 · 2021: 14 · 2020: 9 · 2019: 9 · 2018: 7 · 2017: 3 · 2016: 10 · 2015: 12 · 2014: 5
- FWCI
- 8.04
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Nephrology Dialysis Transplantation (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Transplantation › Renal Transplantation Outcomes and Treatments
- Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
- Keywords
- post-transplant diabetes mellitus, kidney transplantation, DPP-4 inhibitors, insulin secretion, hyperglycemia, endothelial function, cardiovascular risk markers, hypoglycemia, glipizide, immunosuppressive therapy, plasma glucose control, oral glucose tolerance test, insulin resistance, drug safety and tolerability, crossover trial
- MeSH terms
- Sitagliptin Phosphate, Aged, Blood Glucose, Diabetes Mellitus, Dose-Response Relationship, Drug, Female, Follow-Up Studies, Humans, Hypoglycemic Agents, Kidney Failure, Chronic, Male, Middle Aged, Prospective Studies, Pyrazines, Risk Factors, Time Factors, Triazoles, Kidney Transplantation, Treatment Outcome, Cross-Over Studies, Postprandial Period, Glucagon-Like Peptide 1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.